COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Locanabio develops AAV-delivered RNA-targeting gene therapies using engineered snRNAs, Cas13d, and PUF platforms to enable exon skipping, RNA editing, and single-administration treatments for neuromuscular, neurodegenerative, and retinal diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
